227 related articles for article (PubMed ID: 25872771)
1. Ryanodine receptors are targeted by anti-apoptotic Bcl-XL involving its BH4 domain and Lys87 from its BH3 domain.
Vervliet T; Lemmens I; Vandermarliere E; Decrock E; Ivanova H; Monaco G; Sorrentino V; Nadif Kasri N; Missiaen L; Martens L; De Smedt H; Leybaert L; Parys JB; Tavernier J; Bultynck G
Sci Rep; 2015 Apr; 5():9641. PubMed ID: 25872771
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 binds to and inhibits ryanodine receptors.
Vervliet T; Decrock E; Molgó J; Sorrentino V; Missiaen L; Leybaert L; De Smedt H; Kasri NN; Parys JB; Bultynck G
J Cell Sci; 2014 Jun; 127(Pt 12):2782-92. PubMed ID: 24762814
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.
Vervliet T; Parys JB; Bultynck G
Biochem Soc Trans; 2015 Jun; 43(3):396-404. PubMed ID: 26009182
[TBL] [Abstract][Full Text] [Related]
4. The BH4 domain of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca2+ signals to mitochondria.
Monaco G; Decrock E; Arbel N; van Vliet AR; La Rovere RM; De Smedt H; Parys JB; Agostinis P; Leybaert L; Shoshan-Barmatz V; Bultynck G
J Biol Chem; 2015 Apr; 290(14):9150-61. PubMed ID: 25681439
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties.
Vervliet T; Lemmens I; Welkenhuyzen K; Tavernier J; Parys JB; Bultynck G
Biochem Biophys Res Commun; 2015 Jul; 463(3):174-9. PubMed ID: 25957473
[TBL] [Abstract][Full Text] [Related]
6. BH4 domain peptides derived from Bcl-2/Bcl-XL as novel tools against acute pancreatitis.
Vervliet T; Gerasimenko JV; Ferdek PE; Jakubowska MA; Petersen OH; Gerasimenko OV; Bultynck G
Cell Death Discov; 2018; 4():58. PubMed ID: 29760956
[TBL] [Abstract][Full Text] [Related]
7. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
8. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl.
Monaco G; Decrock E; Akl H; Ponsaerts R; Vervliet T; Luyten T; De Maeyer M; Missiaen L; Distelhorst CW; De Smedt H; Parys JB; Leybaert L; Bultynck G
Cell Death Differ; 2012 Feb; 19(2):295-309. PubMed ID: 21818117
[TBL] [Abstract][Full Text] [Related]
9. Biphasic regulation of InsP3 receptor gating by dual Ca2+ release channel BH3-like domains mediates Bcl-xL control of cell viability.
Yang J; Vais H; Gu W; Foskett JK
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1953-62. PubMed ID: 26976600
[TBL] [Abstract][Full Text] [Related]
10. The N-terminus and alpha-5, alpha-6 helices of the pro-apoptotic protein Bax, modulate functional interactions with the anti-apoptotic protein Bcl-xL.
Parikh N; Koshy C; Dhayabaran V; Perumalsamy LR; Sowdhamini R; Sarin A
BMC Cell Biol; 2007 May; 8():16. PubMed ID: 17519046
[TBL] [Abstract][Full Text] [Related]
11. Bcl-xL acts as an inhibitor of IP
Rosa N; Ivanova H; Wagner LE; Kale J; La Rovere R; Welkenhuyzen K; Louros N; Karamanou S; Shabardina V; Lemmens I; Vandermarliere E; Hamada K; Ando H; Rousseau F; Schymkowitz J; Tavernier J; Mikoshiba K; Economou A; Andrews DW; Parys JB; Yule DI; Bultynck G
Cell Death Differ; 2022 Apr; 29(4):788-805. PubMed ID: 34750538
[TBL] [Abstract][Full Text] [Related]
12. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
Monaco G; Vervliet T; Akl H; Bultynck G
Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
[TBL] [Abstract][Full Text] [Related]
13. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP
Ivanova H; Luyten T; Decrock E; Vervliet T; Leybaert L; Parys JB; Bultynck G
Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071
[TBL] [Abstract][Full Text] [Related]
14. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
15. Structural transition in Bcl-xL and its potential association with mitochondrial calcium ion transport.
Rajan S; Choi M; Nguyen QT; Ye H; Liu W; Toh HT; Kang C; Kamariah N; Li C; Huang H; White C; Baek K; Grüber G; Yoon HS
Sci Rep; 2015 May; 5():10609. PubMed ID: 26023881
[TBL] [Abstract][Full Text] [Related]
16. Basal ryanodine receptor activity suppresses autophagic flux.
Vervliet T; Pintelon I; Welkenhuyzen K; Bootman MD; Bannai H; Mikoshiba K; Martinet W; Nadif Kasri N; Parys JB; Bultynck G
Biochem Pharmacol; 2017 May; 132():133-142. PubMed ID: 28322744
[TBL] [Abstract][Full Text] [Related]
17. A conserved hydrophobic core at Bcl-xL mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein.
Feng Y; Zhang L; Hu T; Shen X; Ding J; Chen K; Jiang H; Liu D
Arch Biochem Biophys; 2009 Apr; 484(1):46-54. PubMed ID: 19161970
[TBL] [Abstract][Full Text] [Related]
18. Profiling of the Bcl-2/Bcl-X(L)-binding sites on type 1 IP(3) receptor.
Monaco G; Beckers M; Ivanova H; Missiaen L; Parys JB; De Smedt H; Bultynck G
Biochem Biophys Res Commun; 2012 Nov; 428(1):31-5. PubMed ID: 23058917
[TBL] [Abstract][Full Text] [Related]
19. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G
FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545
[TBL] [Abstract][Full Text] [Related]
20. TCTP contains a BH3-like domain, which instead of inhibiting, activates Bcl-xL.
Thébault S; Agez M; Chi X; Stojko J; Cura V; Telerman SB; Maillet L; Gautier F; Billas-Massobrio I; Birck C; Troffer-Charlier N; Karafin T; Honoré J; Senff-Ribeiro A; Montessuit S; Johnson CM; Juin P; Cianférani S; Martinou JC; Andrews DW; Amson R; Telerman A; Cavarelli J
Sci Rep; 2016 Jan; 6():19725. PubMed ID: 26813996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
